MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH: Form 990, tax year 2012

View the entire original 990 at ProPublica ↗

Organization: MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH (EIN 13-4141945)
Tax period: 2012-01-01 to 2012-12-31
Filed: 2013-05-14
IRS object ID: 201321349349302482
Schema version: 2012v2.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2013-05-14T12:41:12-05:00	Timestamp
Tax Period End Date	2012-12-31	TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	EISNERAMPER LLP	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	750 THIRD AVENUE	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100172703	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2012-01-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	134141945	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	THE MICHAEL J FOX FOUNDATION	BusinessNameLine1
Business Name Line2	FOR PARKINSON'S RESEARCH	BusinessNameLine2

Field	Value	IRS element (for citing)
In Care Of Name	% % STEPHEN GRUBB - MJFF	InCareOfName
Name Control	MICH	NameControl
Phone	2125090995	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	GRAND CENTRAL STATION	AddressLine1
Address Line2	PO BOX 4777 Suite	AddressLine2
City	NEW YORK	City
State	NY	State
ZIP Code	101634777	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	JOANNE MARTZ	Name
Title	CHIEF FINANCIAL & ADMIN OFFICER	Title
Phone	2125290995	Phone
Date Signed	2013-05-14	DateSigned
Authorize Third Party	true	AuthorizeThirdParty

Preparer Preparer

Field	Value	IRS element (for citing)
Phone	2129498700	Phone

Field	Value	IRS element (for citing)
Tax Year	2012	TaxYear
Build TS	2016-03-07 17:11:31Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Name Of Principal Officer Person	Todd Sherer	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	GRAND CENTRAL STN PO BOX 4777	AddressLine1
City	NY	City
State	NY	State
ZIP Code	101634777	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	122037106	GrossReceipts
Group Return For Affiliates	false	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	www.michaeljfox.org	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	2000	YearFormation
State Legal Domicile	DE	StateLegalDomicile
Activity Or Mission Description	THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.	ActivityOrMissionDescription
Nbr Voting Members Governing Body	29	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	28	NbrIndependentVotingMembers
Total Nbr Employees	84	TotalNbrEmployees
Total Nbr Volunteers	17	TotalNbrVolunteers
Total Gross UBI	18055	TotalGrossUBI
Net Unrelated Business Txbl Income	210	NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year	64970818	ContributionsGrantsPriorYear
Contributions Grants Current Year	87327249	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	0	ProgramServiceRevenuePriorYear
Program Service Revenue CY	0	ProgramServiceRevenueCY
Investment Income Prior Year	174041	InvestmentIncomePriorYear
Investment Income Current Year	25786	InvestmentIncomeCurrentYear
Other Revenue Prior Year	38514	OtherRevenuePriorYear
Other Revenue Current Year	183056	OtherRevenueCurrentYear
Total Revenue Prior Year	65183373	TotalRevenuePriorYear
Total Revenue Current Year	87536091	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	53857613	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	55079865	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	6906870	SalariesEtcPriorYear
Salaries Etc Current Year	8458578	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	60000	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	0	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	5746832	TotalFundrsngExpCurrentYear
Other Expense Prior Year	4814498	OtherExpensePriorYear
Other Expenses Current Year	6708348	OtherExpensesCurrentYear
Total Expenses Prior Year	65638981	TotalExpensesPriorYear
Total Expenses Current Year	70246791	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	-455608	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	17289300	RevenuesLessExpensesCY
Total Assets BOY	95542240	TotalAssetsBOY
Total Assets EOY	105378503	TotalAssetsEOY
Total Liabilities BOY	74420395	TotalLiabilitiesBOY
Total Liabilities EOY	66960964	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	21121845	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	38417539	NetAssetsOrFundBalancesEOY
Info In Schedule O Part III	X	InfoInScheduleOPartIII
Mission Description	THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.	MissionDescription
Significant New Program Services	false	SignificantNewProgramServices
Significant Change	false	SignificantChange
Expense	62657563	Expense
Grants	55079865	Grants
Description	TO FUND RESEARCH FOCUSED ON DEVELOPING A CURE FOR PARKINSON'S DISEASE.	Description
Total Program Service Expense	62657563	TotalProgramServiceExpense
Described In501 C3	true	DescribedIn501C3
Schedule B Required	true	ScheduleBRequired
Political Activities	false	PoliticalActivities
Lobbying Activities	false	LobbyingActivities
Subject To Proxy Tax	false	SubjectToProxyTax
Donor Advised Funds	false	DonorAdvisedFunds
Conservation Easements	false	ConservationEasements
Collections Of Art	false	CollectionsOfArt
Credit Counseling	false	CreditCounseling
Term Or Permanent Endowments	false	TermOrPermanentEndowments
Report Land Bldg Equip	true	ReportLandBldgEquip
Report Invest Oth Securities	false	ReportInvestOthSecurities
Report Prog Rel Invest	false	ReportProgRelInvest
Report Other Assets	false	ReportOtherAssets
Report Other Liabilities	true	ReportOtherLiabilities
Report Fin48 Footnote	true	ReportFin48Footnote
Independent Audit Financial Stmt	false	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	true	ConsolidatedAuditFinancialStmt
School	false	School
Foreign Office	true	ForeignOffice
Foreign Activities	true	ForeignActivities
More Than5000 K To Organizations	true	MoreThan5000KToOrganizations
More Than5000 K To Individuals	true	MoreThan5000KToIndividuals
Professional Fundraising	true	ProfessionalFundraising
Fundraising Activities	true	FundraisingActivities
Gaming	false	Gaming
Hospital	false	Hospital
Grants To Organizations	true	GrantsToOrganizations
Grants To Individuals	false	GrantsToIndividuals
Schedule J Required	true	ScheduleJRequired
Tax Exempt Bonds	false	TaxExemptBonds
Excess Benefit Transaction	false	ExcessBenefitTransaction
Prior Excess Benefit Transaction	false	PriorExcessBenefitTransaction
Loan To Officer Or DQP	false	LoanToOfficerOrDQP
Grant To Related Person	false	GrantToRelatedPerson
Bsnss Rltnshp With Organization	false	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	false	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	false	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	true	DeductibleNonCashContributions
Deductible Contributions Of Art	false	DeductibleContributionsOfArt
Terminated	false	Terminated
Partial Liquidation	false	PartialLiquidation
Disregarded Entity	false	DisregardedEntity
Related Entity	true	RelatedEntity
Related Org Controlled Entity	false	RelatedOrgControlledEntity
Transfers To Exempt Non Chrtbl Org	false	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	false	ActivitiesConductedPartnership
Schedule O Required	true	ScheduleORequired
Number Forms Transmitted With1096	114	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	true	ComplianceWithBackupWitholding
Number Of Employees	84	NumberOfEmployees
Employment Tax Returns Filed	true	EmploymentTaxReturnsFiled
Unrelated Business Income	true	UnrelatedBusinessIncome
Form990-T Filed	true	Form990-TFiled
Foreign Financial Account	true	ForeignFinancialAccount
Name Of Foreign Country	CA	NameOfForeignCountry
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTrans
Taxable Party Notification	false	TaxablePartyNotification
Non Deductible Contributions	false	NonDeductibleContributions
Quid Pro Quo Contributions	true	QuidProQuoContributions
Quid Pro Quo Disclosure	true	QuidProQuoDisclosure
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOf
Funds To Pay Premiums	false	FundsToPayPremiums
Premiums Paid	false	PremiumsPaid
Indoor Tanning Services	false	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	29	NbrVotingGoverningBodyMembers
Number Independent Voting Members	28	NumberIndependentVotingMembers
Family Or Business Relationship	true	FamilyOrBusinessRelationship
Delegation Of Management Duties	false	DelegationOfManagementDuties
Changes To Organizing Docs	true	ChangesToOrganizingDocs
Material Diversion Or Misuse	false	MaterialDiversionOrMisuse
Members Or Stockholders	false	MembersOrStockholders
Election Of Board Members	false	ElectionOfBoardMembers
Decisions Subject To Approval	false	DecisionsSubjectToApproval
Minutes Of Governing Body	true	MinutesOfGoverningBody
Minutes Of Committees	true	MinutesOfCommittees
Officer Mailing Address	false	OfficerMailingAddress
Local Chapters	false	LocalChapters
Form990 Provided To Governing Body	true	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	true	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	true	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	true	RegularMonitoringEnforcement
Whistleblower Policy	true	WhistleblowerPolicy
Document Retention Policy	true	DocumentRetentionPolicy
Compensation Process CEO	true	CompensationProcessCEO
Compensation Process Other	true	CompensationProcessOther
Investment In Joint Venture	false	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CO	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	FL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	GA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	IL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ME	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MD	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NJ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NM	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ND	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	PA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	RI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	SC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	TN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	UT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	VA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WV	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WI	StatesWhereCopyOfReturnIsFiled
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Field	Value	IRS element (for citing)
Name Person	STEPHEN GRUBB - MJFF	NamePerson
Telephone Number	2125090995	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	GRAND CENTRAL STATION PO BOX 477	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	101634777	ZIPCode

Field	Value	IRS element (for citing)
Info In Schedule O Part VII	X	InfoInScheduleOPartVII

Form990 Part VII Section A Form990PartVIISectionA (39 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	Reportable Comp From OrganizationReportableCompFromOrganization	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs	Other CompensationOtherCompensation	OfficerOfficer	Average Hours Per Week RelatedAverageHoursPerWeekRelated	Key EmployeeKeyEmployee	Highest Compensated EmployeeHighestCompensatedEmployee
Michael J Fox
Founder	2.0	X	0	0	0
Robert W Shackleton
Chairman	2.0	X	0	0	0	X
George E Prescott
VICE CHAIRMAN	2.0	X	0	0	0	X
Fred G Weiss
Treasurer	2.0	X	0	0	0	X
Holly S Andersen MD
Member	2.0	X	0	0	0
Eva Andersson-Dubin MD
Member	2.0	X	0	0	0
Jon Brooks
Member	2.0	X	0	0	0
Mark Booth
Member	2.0	X	0	0	0
Barry J Cohen
Member	2.0	X	0	0	0
Donny Deutsch
Member	2.0	X	0	0	0
David Einhorn
Member	2.0	X	0	0	0
Karen Finerman
Member	2.0	X	0	0	0
Nelle Fortenberry
Member	2.0	X	0	0	0
Albert B Glickman
Member	2.0	X	0	0	0
David Golub
Member	2.0	X	0	0	0
Mark L Hart III
Member	2.0	X	0	0	0
Skip Irving
Member	2.0	X	0	0	0
Edward Kalikow
Member	2.0	X	0	0	0
Katheen Kennedy
Member	2.0	X	0	0	0
Amar Kuchinad
Member	2.0	X	0	0	0
Edwin A Levy
Member	2.0	X	0	0	0
Marc S Lipschultz
Member	2.0	X	0	0	0
Douglas I Ostrover
Member	2.0	X	0	0	0
Tracy Pollan
Member	2.0	X	0	0	0
Ryan Reynolds
Member	2.0	X	0	0	0
Frederick E Rowe Jr
Member	2.0	X	0	0	0
Lily Safra
Member	2.0	X	0	0	0
Curtis Schenker
Member	2.0	X	0	0	0
George Whelen
Member	2.0	X	0	0	0		0.0
Todd Sherer
CEO	40.0		445616	0	26090	X
Joanne Martz
Chief Fin and Admin Officer	40.0		295473	0	20048	X
Deborah W Brooks
Co-Founder & Exec. Vice Chair	40.0		510660	0	26090			X
Sohini Chowdhury
Sr. VP, Research Partnerships	40.0		210396	0	12452			X
Sheila Kelly
VP, Development	40.0		184863	0	11685			X
Holly Teichholtz
VP, Marketing & Communications	40.0		145286	0	16907				X
Brian K Fiske
VP, Research Programs	40.0		186700	0	17935				X
Mark A Frasier
VP, Research Programs	40.0		177852	0	5335				X
Alison Urkowitz
VP, Research Operations	40.0		145290	0	10499				X
Laxmi Wordham
Chief Digital Officer	40.0		230440	0	25503				X

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	2532576	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	0	TotalReportableCompFrmRltdOrgs
Total Other Compensation	172544	TotalOtherCompensation
Number Individuals GT100 K	18	NumberIndividualsGT100K
Formers Listed	false	FormersListed
Total Comp GT150 K	true	TotalCompGT150K
Compensation From Other Sources	false	CompensationFromOtherSources

Contractor Compensation ContractorCompensation

Name Of Contractor NameOfContractor

Field	Value	IRS element (for citing)
Name Person	RUDER FINN INC	NamePerson

Address Of Contractor AddressOfContractor

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	301 E 57TH STREET	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	10022	ZIPCode

Field	Value	IRS element (for citing)
Description Of Services	CONSULTING	DescriptionOfServices
Compensation	198726	Compensation

Field	Value	IRS element (for citing)
Number Of Contractors GT100 K	1	NumberOfContractorsGT100K
Fundraising Events	4823361	FundraisingEvents
All Other Contributions	82503888	AllOtherContributions
Noncash Contributions	33493293	NoncashContributions
Total Contributions	87327249	TotalContributions
Total Program Service Revenue	0	TotalProgramServiceRevenue

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	24221	TotalRevenueColumn
Exclusion	$24,221	ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Gross Rents GrossRents

Field	Value	IRS element (for citing)
Real	161299	Real

Rental Income Or Loss RentalIncomeOrLoss

Field	Value	IRS element (for citing)
Real	161299	Real
Personal	0	Personal

Net Rental Income Or Loss NetRentalIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	161299	TotalRevenueColumn
Exclusion	$161,299	ExclusionAmount

Gross Amount Sales Assets GrossAmountSalesAssets

Field	Value	IRS element (for citing)
Securities	33562803	Securities

Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses

Field	Value	IRS element (for citing)
Securities	33561238	Securities

Gain Or Loss GainOrLoss

Field	Value	IRS element (for citing)
Securities	1565	Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	1565	TotalRevenueColumn
Exclusion	$1,565	ExclusionAmount

Field	Value	IRS element (for citing)
Gross Income Fundraising Events	913395	GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events	4529802	CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses	913395	FundraisingDirectExpenses

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income From Gaming NetIncomeFromGaming

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	44887	GrossSalesOfInventory
Cost Of Goods Sold	26382	CostOfGoodsSold

Net Income Or Loss NetIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	18055	TotalRevenueColumn
Unrelated Business Revenue	18055	UnrelatedBusinessRevenue

Other Revenue Misc OtherRevenueMisc

Field	Value	IRS element (for citing)
Description	MISCELLANEOUS REVENUE	Description
Business Code	900099	BusinessCode
Total Revenue Column	3702	TotalRevenueColumn
Exclusion	$3,702	ExclusionAmount

Field	Value	IRS element (for citing)
Total Other Revenue	3702	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	87536091	TotalRevenueColumn
Unrelated Business Revenue	18055	UnrelatedBusinessRevenue
Exclusion	$190,787	ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	37825367	Total
Program Services	37825367	ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

Field	Value	IRS element (for citing)
Total	0	Total

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	17254498	Total
Program Services	17254498	ProgramServices

Benefits To Members BenefitsToMembers

Field	Value	IRS element (for citing)
Total	0	Total

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	1647008	Total
Program Services	807034	ProgramServices
Management And General	263521	ManagementAndGeneral
Fundraising	576453	Fundraising

Comp Disqual Persons CompDisqualPersons

Field	Value	IRS element (for citing)
Total	0	Total

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	5525647	Total
Program Services	2709020	ProgramServices
Management And General	863425	ManagementAndGeneral
Fundraising	1953202	Fundraising

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	188491	Total
Program Services	95280	ProgramServices
Management And General	28151	ManagementAndGeneral
Fundraising	65060	Fundraising

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	609410	Total
Program Services	266543	ProgramServices
Management And General	110539	ManagementAndGeneral
Fundraising	232328	Fundraising

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	488022	Total
Program Services	242038	ProgramServices
Management And General	72573	ManagementAndGeneral
Fundraising	173411	Fundraising

Fees For Services Management FeesForServicesManagement

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	108454	Total
Program Services	98250	ProgramServices
Management And General	731	ManagementAndGeneral
Fundraising	9473	Fundraising

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	37662	Total
Management And General	37662	ManagementAndGeneral

Fees For Services Lobbying FeesForServicesLobbying

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	644425	Total
Program Services	411358	ProgramServices
Management And General	27751	ManagementAndGeneral
Fundraising	205316	Fundraising

Advertising Advertising

Field	Value	IRS element (for citing)
Total	155901	Total
Program Services	68519	ProgramServices
Fundraising	87382	Fundraising

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	809810	Total
Program Services	362312	ProgramServices
Management And General	48725	ManagementAndGeneral
Fundraising	398773	Fundraising

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	407580	Total
Program Services	188218	ProgramServices
Management And General	18941	ManagementAndGeneral
Fundraising	200421	Fundraising

Royalties Royalties

Field	Value	IRS element (for citing)
Total	0	Total

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	1461819	Total
Program Services	730941	ProgramServices
Management And General	225757	ManagementAndGeneral
Fundraising	505121	Fundraising

Travel Travel

Field	Value	IRS element (for citing)
Total	393081	Total
Program Services	126021	ProgramServices
Management And General	15094	ManagementAndGeneral
Fundraising	251966	Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

Field	Value	IRS element (for citing)
Total	0	Total

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	1059786	Total
Program Services	1059786	ProgramServices

Interest Interest

Field	Value	IRS element (for citing)
Total	56420	Total
Management And General	56420	ManagementAndGeneral

Payments To Affiliates PaymentsToAffiliates

Field	Value	IRS element (for citing)
Total	0	Total

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	668503	Total
Program Services	317027	ProgramServices
Management And General	50375	ManagementAndGeneral
Fundraising	301101	Fundraising

Insurance Insurance

Field	Value	IRS element (for citing)
Total	67055	Total
Program Services	54795	ProgramServices
Management And General	3013	ManagementAndGeneral
Fundraising	9247	Fundraising

Other Expenses OtherExpenses (4 entries)

DescriptionDescription	TotalTotal	Program ServicesProgramServices	Management And GeneralManagementAndGeneral	FundraisingFundraising
CREDIT CARD & BROKERAGE FEES	310526	326	15603	294597
OTHER SPECIAL EVENTS EXPENSE	209094			209094
DONATION PROCESSING	78827			78827
MARATHON RUNNER FEES	178983			178983

All Other Expenses AllOtherExpenses

Field	Value	IRS element (for citing)
Total	60422	Total
Program Services	40230	ProgramServices
Management And General	4115	ManagementAndGeneral
Fundraising	16077	Fundraising

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	70246791	Total
Program Services	62657563	ProgramServices
Management And General	1842396	ManagementAndGeneral
Fundraising	5746832	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	104	BOY
EOY	326	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	80371171	BOY
EOY	85393127	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	12027926	BOY
EOY	15199335	EOY

Accounts Receivable AccountsReceivable

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Receivables From Officers Etc ReceivablesFromOfficersEtc

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Receivables From Disqual Persons ReceivablesFromDisqualPersons

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Notes Loans Receivable Net OtherNotesLoansReceivableNet

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	17847	BOY
EOY	19190	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	303256	BOY
EOY	312174	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	3832472	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	1688083	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	653423	BOY
EOY	2144389	EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

Field	Value	IRS element (for citing)
BOY	1339815	BOY
EOY	1478589	EOY

Investments Other Securities InvestmentsOtherSecurities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Investments Program Related InvestmentsProgramRelated

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Intangible Assets IntangibleAssets

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	828698	BOY
EOY	831373	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	95542240	BOY
EOY	105378503	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	1590225	BOY
EOY	2186550	EOY

Grants Payable GrantsPayable

Field	Value	IRS element (for citing)
BOY	56245521	BOY
EOY	62405623	EOY

Deferred Revenue DeferredRevenue

Field	Value	IRS element (for citing)
BOY	14898701	BOY
EOY	0	EOY

Tax Exempt Bond Liabilities TaxExemptBondLiabilities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Escrow Account Liability EscrowAccountLiability

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Loans From Officers Directors LoansFromOfficersDirectors

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Mort Notes Pybl Secured Invest Prop MortNotesPyblSecuredInvestProp

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Unsecured Notes Loans Payable UnsecuredNotesLoansPayable

Field	Value	IRS element (for citing)
BOY	1000196	BOY
EOY	1150196	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	685752	BOY
EOY	1218595	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	74420395	BOY
EOY	66960964	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	5774290	BOY
EOY	18533026	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	15347555	BOY
EOY	19884513	EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	21121845	BOY
EOY	38417539	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	95542240	BOY
EOY	105378503	EOY

Field	Value	IRS element (for citing)
Reconcilation Revenue Expenses	17289300	ReconcilationRevenueExpenses
Reconciliation Unrealized Invest	6394	ReconciliationUnrealizedInvest
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	false	AccountantCompileOrReview
FS Audited	true	FSAudited

FS Audited Basis FSAuditedBasis

Field	Value	IRS element (for citing)
Financial Statement Consolidated	X	FinancialStatementConsolidated

Field	Value	IRS element (for citing)
Audit Committee	true	AuditCommittee
Federal Grant Audit Required	false	FederalGrantAuditRequired

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	42077867	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	51259577	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	57125384	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	64970818	CurrentTaxYearMinus1Year
Current Tax Year	87327249	CurrentTaxYear
Total	302760895	Total

Tax Rev Levied For Org Benefit170 TaxRevLeviedForOrgBenefit170

Field	Value	IRS element (for citing)
Total	0	Total

Value Srvc Fclts Furnished By Govt ValueSrvcFcltsFurnishedByGovt

Field	Value	IRS element (for citing)
Total	0	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	42077867	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	51259577	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	57125384	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	64970818	CurrentTaxYearMinus1Year
Current Tax Year	87327249	CurrentTaxYear
Total	302760895	Total

Field	Value	IRS element (for citing)
Amounts Subst Contributors Total	140078581	AmountsSubstContributorsTotal
Public Support Total170	162682314	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	744930	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	157415	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	232554	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	42326	CurrentTaxYearMinus1Year
Current Tax Year	24221	CurrentTaxYear
Total	1201446	Total

Net UBI NetUBI

Field	Value	IRS element (for citing)
Total	0	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	25682	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	15213	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	34177	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	38514	CurrentTaxYearMinus1Year
Current Tax Year	21757	CurrentTaxYear
Total	135343	Total

Field	Value	IRS element (for citing)
Total Support	304097684	TotalSupport
Public Support Pertcentage170	0.53497	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.59094	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amts		ArtPublicExhibitionAmts
Held Works Of Art Amts		HeldWorksOfArtAmts
Current Year Minus3 Years		CurrentYearMinus3Years
Current Year Minus4 Years		CurrentYearMinus4Years
Land		Land
Buildings		Buildings

Leasehold Improvements LeaseholdImprovements

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	1692761	OtherCostOrOtherBasis
Depreciation	407395	Depreciation
Book Value	1285366	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	1887019	OtherCostOrOtherBasis
Depreciation	1069253	Depreciation
Book Value	817766	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	252692	OtherCostOrOtherBasis
Depreciation	211435	Depreciation
Book Value	41257	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	2144389	TotalOfBookValueLandBuildings
Federal Income Tax Liability	0	FederalIncomeTaxLiability

Other Liabilities OtherLiabilities (3 entries)

DescriptionDescription	AmountAmount
DEFERRED RENT	$897,274
DUE TO MJFF CANADA	$105,926
INTEREST PAYABLE	$215,395

Field	Value	IRS element (for citing)
Total Of Amounts	1218595	TotalOfAmounts
Footnote In Part XIII	X	FootnoteInPartXIII
Tot Revenue Etc Audited Fincl Stmt	87836044	TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments	6394	NetUnrealizedGainsInvestments
Other Revenues	293559	OtherRevenues
Revenue Not Rptd F990	299953	RevenueNotRptdF990
Revenue Subtotal	87536091	RevenueSubtotal
Total Revenue Per Form990	87536091	TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt	70540350	TotExpensesEtcAuditedFinclStmt
Other Expenses Included	293559	OtherExpensesIncluded
Expenses Not Rptd F990	293559	ExpensesNotRptdF990
Expenses Subtotal	70246791	ExpensesSubtotal
Total Expenses Per Form990	70246791	TotalExpensesPerForm990

Form990 Schedule D Part XIII Form990ScheduleDPartXIII (2 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Schedule D, Page 3, Question 2:	ASC 740-10-05 Footnote	The Foundation is subject to the provisions of the Financial Accounting Standards Board's Accounting Standards Codification ("ASC") Topic 740-10-05 relating to accounting and reporting for uncertainty in income taxes. For the Foundation, ASC Topic 740-10-05 is potentially applicable to the incurrence of unrelated business income ("UBIT") attributable to certain of the Foundation's merchandise sales. Nonetheless, because of Foundation's general tax-exempt status, ASC Topic 740-10-05 has not had, and is not expected to have, a material impact on the Foundation's financial statements.
RECONCILIATION OF REVENUE AND EXPENSES	SCHEDULE D, PARTS XII/XIII, LINES 2D, PAGE 4	AMOUNTS REPRESENT REVENUES AND EXPENSES ATTRIBUTABLE TO THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH'S CANADIAN ENTITY.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	true	GrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (5 entries)

RegionRegion	Type Of Activities ConductedTypeOfActivitiesConducted	Total ExpendituresTotalExpenditures
East Asia and the Pacific	Grantmaking	1535455
North America	Grantmaking	4400327
Europe (Including Iceland and Greenland)	Grantmaking	10285793
Middle East and North Africa	Grantmaking	946623
South America	Grantmaking	86300

Field	Value	IRS element (for citing)
Subtotal Amount Spent	17254498	SubtotalAmountSpent
Total Amount Spent	17254498	TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (71 entries)

RegionRegion	Purpose Of GrantPurposeOfGrant	Amount Of Cash GrantAmountOfCashGrant
Europe (Including Iceland and Greenland)	Xenon inhalation to reduce L-DOPA-induced dyskinesia	461577
North America	Development of a non-human primate model of Parkinson's disease alpha-synucleinopathy	502882
Europe (Including Iceland and Greenland)	Modulation of the CD40/CD40-Ligand Neuroinflammation Pathway in Parkinson's Mouse Models	74966
Europe (Including Iceland and Greenland)	Development of an HTS assay to break the alpha- synuclein-glucocerebrosidase feedback loop	74250
Europe (Including Iceland and Greenland)	Small molecule screening for a-synuclein binders using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein	947290
Europe (Including Iceland and Greenland)	Enhanced CNS dopamine availability, prolonged activity and improved dyskinesia profile after administration of selectively deuterated L-DOPA	400000
East Asia and the Pacific	Is the xenomitochondrial mouse an 'ideal' PD model?	36726
North America	Mechanisms of Parkin Recruitment and Mitophagy	199990
North America	A Two-dose Active Comparator, Randomized Cross- over Phase I Trial to Examine the Single Dose Pharmacokinetic Profile of Sublingual Administered APL-130277 as compared to APOKYN in Healthy Volunteers	947925
East Asia and the Pacific	Collaborative validation of oxidized DJ-1 antibodies for PD biomarker study	203655
Europe (Including Iceland and Greenland)	In vivo characterization of helper-dependent adenoviral vectors expressing human LRRK2	112163
Europe (Including Iceland and Greenland)	Regulation of LRRK2 Activity and Toxicity by Nitrosative Stress and S-Nitrosylation: Implications for Idiopathic Parkinson's Disease	133474
Europe (Including Iceland and Greenland)	Novel PD Tools: Generation of Post- translationally Modified Alpha-synuclein	233526
Europe (Including Iceland and Greenland)	VPS35 as a Novel Target for Parkinson's Disease	249806
Europe (Including Iceland and Greenland)	Investigation of the mechanisms involved in a-synuclein secretion in vivo	150000
East Asia and the Pacific	Validation of ATP13a2/PARK9 as a Target to Reduce Neurodegeneration Induced by Alpha-Synuclein	249657
Europe (Including Iceland and Greenland)	Enhancing PD symptom improvement and decreasing adverse event incidence from L-DOPA therapy by improving L-DOPA bioavailability and consistency of absorption through co-administration of the Motilin agonist, GSK962040	78410
Europe (Including Iceland and Greenland)	Anti-parkinson and anti-dyskinetic efficacy studies of HE3286 in a MPTP non-human primate model for Parkinson's disease	431528
Europe (Including Iceland and Greenland)	Protein Interaction network analysis and pathway modeling for LRRK2	1499839
Europe (Including Iceland and Greenland)	Intestinal and nasal microbiota of patients with idiopathic Parkinson's disease	75000
Europe (Including Iceland and Greenland)	PPMI 2012: RBD Core Support for Prodromal PPMI (P-PPMI) in 2013	130000
Europe (Including Iceland and Greenland)	PPMI 2012: Cognitive Categorization Ancillary Study	14063
Europe (Including Iceland and Greenland)	Is PD a low-grade inflammatory bowel disease?	52910
Europe (Including Iceland and Greenland)	IMD-026259 - An Innovative Drug for Disease- Modifying Treatment of Parkinson's Disease	499989
Europe (Including Iceland and Greenland)	Cognitive phenotypes in Parkinson's disease: anatomical and functional correlates	366025
Europe (Including Iceland and Greenland)	The role of mGluR4 in the modulation of L-DOPA- induced motor performance and dyskinesia in a rat model of Parkinson's disease - 2012	35689
Europe (Including Iceland and Greenland)	Neurotrophic and autophagic markers in Parkinson's disease: Implications for disease- modifying strategies	60000
Europe (Including Iceland and Greenland)	Functional Integration of Grafted Human Induced Neuronal (iN) Cells in Parkinson's Disease	74951
Europe (Including Iceland and Greenland)	Validation of IGF-1 as a neuroprotective agent in animal models of Parkinson?s disease	110000
Europe (Including Iceland and Greenland)	Preclinical validation of a Nurr1 agonist for neuroprotection in Parkinson's disease	115500
Europe (Including Iceland and Greenland)	Transfer of alpha-synuclein between the brain and peripheral organs	200000
Europe (Including Iceland and Greenland)	Regulated GDNF gene therapy- a novel regulatory system based on protein degradation.	219451
Europe (Including Iceland and Greenland)	PDGene Extension	58307
North America	Stimulation of protein clearance mechanisms to improve clearance of toxic accumulations of alpha-synuclein protein in Parkinson's disease	75000
Europe (Including Iceland and Greenland)	PPMI 2012: rsMRI Ancillary Study	9688
Europe (Including Iceland and Greenland)	PPMI 2012: Cognitive Categorization Ancillary Study	11250
Europe (Including Iceland and Greenland)	Laboratory phenotyping of Parkinson disease subjects using a multiplex approach	222023
Europe (Including Iceland and Greenland)	PPMI Clinical Trial Site: Year Two	258781
Europe (Including Iceland and Greenland)	The role of brain-specific PGC-1alpha isoforms in Parkinson Disease	75000
Europe (Including Iceland and Greenland)	Clinical Coordination of LRRK2 Cohort Consortium- Supplement	24259
Europe (Including Iceland and Greenland)	Lead optimization for a Parkinson's Disease therapeutic	399894
Europe (Including Iceland and Greenland)	Trace amines and their metabolites as potential heraldic markers in Parkinson's disease	74986
Europe (Including Iceland and Greenland)	PPMI Clinical Trial Site - SWEDD Amendment	59438
Europe (Including Iceland and Greenland)	Ceruloplasmin deamidation in Parkinson's disease cerebrospinal fluid: gain of pro-adhesive function	73150
North America	Sanofi Packaging and distribution project	19467
Middle East and North Africa	LRRK2 Cohort Consortium Biorepository Agreement- Tel Aviv	946623
Europe (Including Iceland and Greenland)	Attenuation of neuroinflammation by brain- targeted liposomal methylprednisolone (2B3-201)	75000
Europe (Including Iceland and Greenland)	Characterizing region specific splice isoforms of LRRK2	124935
Europe (Including Iceland and Greenland)	Cannabinoid CB2 receptors as a new target for the treatment of disease progression in Parkinson's disease: studies in LRRK2-transgenic mice	146258
North America	Development of L-745,870, a selective D4 receptor antagonist, for the treatment of L-DOPA-induced dyskinesia	1086711
Europe (Including Iceland and Greenland)	CD163+ macrophages as tools for neuroinflammatory modulation in Parkinson's disease	74745
Europe (Including Iceland and Greenland)	Cleaved Cerebrospinal Fluid Proteins as Early Biomarkers for Detection of Parkinson's Disease	92640
North America	Investigation of neuroinflammation in LRRK2 mutation carriers using positron emission tomography	249947
North America	Imaging Neuroinflammation in LRRK2 Rat Models of Parkinson's Disease	296533
North America	Pharmacological targeting of the 5-HT1, A2A and NMDA receptors: an integrative approach to dyskinesia	389400
South America	Targeting the unfolded protein response transcription factor XBP1 to alleviate neurodegeneration triggered by alpha-synuclein.	86300
East Asia and the Pacific	LRRK2 HD-AD5 Subcloning work	9468
East Asia and the Pacific	Generation of phospho-PINK1 and phospho-Parkin Antibodies	18553
East Asia and the Pacific	Combining mass spectrometry with genetic and pharmacological approaches to discover and validate LRRK2 substrates	1500057
Europe (Including Iceland and Greenland)	Effects of recombinant CDNF protein in alpha- synuclein model of Parkinson's disease in rats	125000
Europe (Including Iceland and Greenland)	PPMI 2012: Cognitive Categorization Ancillary Study	7969
Europe (Including Iceland and Greenland)	PPMI 2012: rsMRI Ancillary Study	9688
East Asia and the Pacific	Alpha synuclein as a major regulator of iron homeostasis	62203
North America	LRRK2 regulates host response to microbial infections	250000
East Asia and the Pacific	Evaluating a targeted cognitive training program for the treatment of Freezing of Gait	490663
North America	A novel protease pathway in Parkinson's disease	74586
North America	Biomarkers of PD risk in LRRK2 mutation carriers	466755
North America	Validation of Sirtuin 3 as a Neuroprotective Target in Parkinson's Disease	250000
Europe (Including Iceland and Greenland)	PPMI 2012: rsMRI Ancillary Study	9688
Europe (Including Iceland and Greenland)	PPMI 2012: Cognitive Categorization Ancillary Study	15469
Europe (Including Iceland and Greenland)	Polyglutamine repeats and Parkinson disease	74800

Field	Value	IRS element (for citing)
Total Number Of501c3 Orgs	55	TotalNumberOf501c3Orgs
Total Number Of Other Orgs	16	TotalNumberOfOtherOrgs
Transfer To Foreign Corp	false	TransferToForeignCorp
Interest In Foreign Trust	false	InterestInForeignTrust
Own Foreign Corp	false	OwnForeignCorp
Passive Foreign Invest Co	false	PassiveForeignInvestCo
Foreign Partnership	false	ForeignPartnership
Boycott Countries	false	BoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV

Field	Value	IRS element (for citing)
Identifier	SCHEDULE F	Identifier
Return Reference	PROCEDURES FOR MONITORING GRANT FUNDS OUTSIDE THE UNITED STATES:	ReturnReference
Explanation	THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.	Explanation

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	X	MailSolicitations
Email Solicitations	X	EmailSolicitations
Solicitation Of Non Govt Grants	X	SolicitationOfNonGovtGrants
Special Fundraising Events	X	SpecialFundraisingEvents
Agreement Ref Fundraising	true	AgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation

Field	Value	IRS element (for citing)
Name Of Individual	Event Associates Inc	NameOfIndividual
Activity	Fundraising Consulting	Activity
Fundraiser Control Of Funds	false	FundraiserControlOfFunds
Gross Receipts	0	GrossReceipts
Amount Retained By Contractor	60000	AmountRetainedByContractor
Net To Organization	0	NetToOrganization

Field	Value	IRS element (for citing)
Total Gross Receipts	0	TotalGrossReceipts
Total Retained By Contractors	60000	TotalRetainedByContractors
Total Net To Organization	0	TotalNetToOrganization
Licensed States	AL	LicensedStates
Licensed States	AK	LicensedStates
Licensed States	AZ	LicensedStates
Licensed States	AR	LicensedStates
Licensed States	CA	LicensedStates
Licensed States	CO	LicensedStates
Licensed States	CT	LicensedStates
Licensed States	FL	LicensedStates
Licensed States	GA	LicensedStates
Licensed States	IL	LicensedStates
Licensed States	KS	LicensedStates
Licensed States	KY	LicensedStates
Licensed States	ME	LicensedStates
Licensed States	MD	LicensedStates
Licensed States	MA	LicensedStates
Licensed States	MI	LicensedStates
Licensed States	MN	LicensedStates
Licensed States	MS	LicensedStates
Licensed States	NH	LicensedStates
Licensed States	NJ	LicensedStates
Licensed States	NM	LicensedStates
Licensed States	NY	LicensedStates
Licensed States	NC	LicensedStates
Licensed States	ND	LicensedStates
Licensed States	OH	LicensedStates
Licensed States	OK	LicensedStates
Licensed States	OR	LicensedStates
Licensed States	PA	LicensedStates
Licensed States	RI	LicensedStates
Licensed States	SC	LicensedStates
Licensed States	TN	LicensedStates
Licensed States	UT	LicensedStates
Licensed States	VA	LicensedStates
Licensed States	WA	LicensedStates
Licensed States	WV	LicensedStates
Licensed States	WI	LicensedStates

Events Information EventsInformation

Field	Value	IRS element (for citing)
Name Of Event1	FUNNY THING	NameOfEvent1
Gross Receipts Event1	4225532	GrossReceiptsEvent1
Charitable Contributions Event1	3520856	CharitableContributionsEvent1
Gross Revenue Event1	704676	GrossRevenueEvent1
Cash Prizes Event1	0	CashPrizesEvent1
Non Cash Prizes Event1	0	NonCashPrizesEvent1
Rent Facility Costs Event1	447540	RentFacilityCostsEvent1
Food And Beverage Event1	0	FoodAndBeverageEvent1
Entertainment Event1	238355	EntertainmentEvent1
Other Direct Expenses Event1	18780	OtherDirectExpensesEvent1
Name Of Event2	BREAKING PAR	NameOfEvent2
Gross Receipts Event2	614840	GrossReceiptsEvent2
Charitable Contributions Event2	489652	CharitableContributionsEvent2
Gross Revenue Event2	125188	GrossRevenueEvent2
Cash Prizes Event2	0	CashPrizesEvent2
Non Cash Prizes Event2	0	NonCashPrizesEvent2
Rent Facility Costs Event2	107838	RentFacilityCostsEvent2
Food And Beverage Event2	0	FoodAndBeverageEvent2
Other Direct Expenses Event2	17350	OtherDirectExpensesEvent2
Total Number Of Other Events	3	TotalNumberOfOtherEvents
Gross Receipts Other Events	602825	GrossReceiptsOtherEvents
Charitable Contrib Other Events	519294	CharitableContribOtherEvents
Gross Revenue Other Events	83531	GrossRevenueOtherEvents
Cash Prizes Other Events	0	CashPrizesOtherEvents
Non Cash Prizes Other Events	3263	NonCashPrizesOtherEvents
Rent Facility Costs Other Events	60858	RentFacilityCostsOtherEvents
Food And Beverage Other Events	0	FoodAndBeverageOtherEvents
Entertainment Other Events	16471	EntertainmentOtherEvents
Other Direct Expenses Other Events	2940	OtherDirectExpensesOtherEvents
Gross Receipts Total	5443197	GrossReceiptsTotal
Charitable Contributions Total	4529802	CharitableContributionsTotal
Gross Revenue Total Events	913395	GrossRevenueTotalEvents
Cash Prizes Total Events	0	CashPrizesTotalEvents
Non Cash Prizes Total Events	3263	NonCashPrizesTotalEvents
Rent Facility Costs Total Events	616236	RentFacilityCostsTotalEvents
Food And Beverage Total Events	0	FoodAndBeverageTotalEvents
Entertainment Total Events	254826	EntertainmentTotalEvents
Other Direct Expenses Total Events	39070	OtherDirectExpensesTotalEvents
Direct Expense Summary Events	913395	DirectExpenseSummaryEvents

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Records Maintained	true	RecordsMaintained

Recipient Table RecipientTable (222 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EIN Of RecipientEINOfRecipient	IRC SectionIRCSection	Amount Of Cash GrantAmountOfCashGrant	Purpose Of GrantPurposeOfGrant
23andMe Inc
2606 Bayshore Parkway	Mountain View	CA	94043	204857371	Public Sector	26400	Using external research experts to mine the 23andMe Parkinson's dataset
23andMe Inc
2606 Bayshore Parkway	Mountain View	CA	94043	204857371	Public Sector	291428	23andMe Blood Collection for the LRRK2 Consortium
Acadia Pharmaceuticals
3911 Sorrento Valley Blvd	San Diego	CA	92121	061376651	Public Sector	322414	Development of Nurr1-RXR heterodimer selective agonists for Parkinson's disease
Alnylam Pharmaceuticals
300 Third Street	Cambridge	MA	02142	770602661	Public Sector	25000	Therapeutic Development of siRNA Targeting Alpha-Synuclein
Alnylam Pharmaceuticals
300 Third Street	Cambridge	MA	02142	770602661	Public Sector	162668	Therapeutic Development of siRNA Targeting Alpha-Synuclein
Aperio Technologies
1360 Park Center Drive	Vista	CA	92081	330939292	Public Sector	10530	Aperio Website Hosting of Immunohistological Slides -LRRK2
Avanir Pharmaceuticals
20 Enterprise	Orange	CA	92121	330314804	Public Sector	569151	AVP-923 (dextromethorphan hydrobromide and quinidine sulfate) for levodopa induced dyskinesia in Parkinson's disease
Banner Sun Health Research Institute
10515 W Santa Fe Drive	Sun City	AZ	85351	860768795	501(c)(3)	8438	PPMI 2012: Cognitive Categorization Ancillary Study
Banner Sun Health Research Institute
10515 W Santa Fe Drive	Sun City	AZ	85351	860768795	501(c)(3)	15000	APDC Reviewer compensation
Banner Sun Health Research Institute
10515 W Santa Fe Drive	Sun City	AZ	85351	860768795	501(c)(3)	50000	AV-133: PPMI Ancillary Study
Baylor College of Medicine
6550 Fannin St Suite 1801	Houston	TX	77030	741613878	501(c)(3)	9688	PPMI 2012: rsMRI Ancillary
Baylor College of Medicine
6550 Fannin St Suite 1801	Houston	TX	77030	741613878	501(c)(3)	13125	PPMI 2012: Cognitive Categorization Ancillary Study
Baylor College of Medicine
One Baylor Plaza Room 630E	Houston	TX	77030	741613878	501(c)(3)	45000	Generation of HD-Ad Type 5 LRRK2 expression vectors
Baylor College of Medicine
6550 Fannin St Suite 1801	Houston	TX	77030	741613878	501(c)(3)	50000	AV-133: PPMI Ancillary Study
Beth Israel Deaconess Medical Center
330 Brookline Ave Room CLS-638	Boston	MA	02445	042103881	501(c)(3)	75000	Irisin: A novel PGC-1alpha related target for neuroprotection in Parkinson's Disease
Beth Israel Medical Center
10 Union Square East Suite 2Q	New York	NY	10003	135564934	501(c)(3)	142156	Planning Phase for LARRI
Beth Israel Medical Center
10 Union Square East PACC Suite 5	New York	NY	10003	135564934	501(c)(3)	509385	LRRK2 Mutations and Cancer Risk
Biomer Technology
1047 Serpentine Lane Bldg 200	Pleasantown	CA	94566	481286101	Public Sector	62000	Post-Translationally Modified Alpha-Synuclein: Generation and Ligation of modified Peptides to Alpha-Synuclein Protein
Board of Regents of the University of Wisconsin
600 Highland Ave K4/7 CSC	Madison	WI	53792	396006492	501(c)(3)	79955	Characterization of vocalization and swallowing deficits in Pink1 knockout rats
Boston University
Robinson C-329 715 Albany St	Boston	MA	02118	042103545	501(c)(3)	12656	PPMI 2012: Cognitive Categorization Ancillary Study
Boston University
Robinson C-329 715 Albany St	Boston	MA	02118	042103545	501(c)(3)	137500	PPMI Clinical Trial Site: Year Two
Boston University
Robinson C-329 715 Albany St	Boston	MA	02118	042103545	501(c)(3)	150000	PPMI Clinical Trial Site: Year Three
Boston University
72 East Concord St L-606B	Boston	MA	02118	042103545	501(c)(3)	274219	Clinical evaluation of LRRK2 inhibitors on inflammatory responses in Crohn's and Parkinson's diseases
Brigham & Women's Hospital
65 Landsdowne Street	Boston	MA	02139	042312909	501(c)(3)	71607	Evaluation of PD-linked transcripts in PPMI
City College of New York
1230 York Avenue Box 296	New York	NY	10065	131624158	501(c)(3)	147301	The Role of CK2 in the development of L-DOPA- induced dyskinesia in Parkinson's disease
Cleveland Clinic
9500 Euclid Avenue S-31	Cleveland	OH	44195	340714585	501(c)(3)	9688	PPMI 2012: rsMRI Ancillary Study
Cleveland Clinic
9500 Euclid Avenue S-31	Cleveland	OH	44195	340714585	501(c)(3)	12188	PPMI 2012: Cognitive Categorization Ancillary Study
Colorado State University
1680 Campus Delivery	Fort Collins	CO	805231680	846000545	501(c)(3)	112170	Targeting Nurr1 with novel diindolymethane compounds
Columbia University
710 W168th St 3rd floor	New York	NY	10032	135598093	501(c)(3)	112500	BioFIND Clinical Trial Site- Columbia University
Coriell Institute for Medical Research
403 Haddon Avenue	Camden	NJ	08103	210672684	501(c)(3)	5201	Collection, storage and distribution of MJFF samples from AVE8112 MAD study
Coriell Institute for Medical Research
403 Haddon Avenue	Camden	NJ	08103	210672684	501(c)(3)	281480	23andme LRRK2 Cohort Consortium Biorepository Agreement
Coriell Institute for Medical Research
403 Haddon Avenue	Camden	NJ	08103	210672684	501(c)(3)	354062	LRRK2 Cohort Consortium: Coriell Biorepository Supplement
Coriell Institute for Medical Research
403 Haddon Avenue	Camden	NJ	08103	210672684	501(c)(3)	700000	PPMI 2012: BioRepository Funding for 2012-2013
Covance
180 Rustcraft Road	Dedham	MA	02026	223265977	Public Sector	26480	RE-evaluation of the Qualification samples for DJ-1
Covance
180 Rustcraft Road	Dedham	MA	02026	223265977	Public Sector	43000	CSF Hemoglobin Assay
Covance
180 Rustcraft Road	Dedham	MA	02026	223265977	Public Sector	65751	PPMI 2012: Covance Funding for Australia Expansion
Covance
180 Rustcraft Road	Dedham	MA	02026	223265977	Public Sector	137500	Covance antibody testing, optimization and assay validation for Full Length LRRK2 P.O.# CAP08192012.
DiaLean Ltd
675 US Highway One	North Brunswick	NJ	08902		Public Sector	205996	DLN-101 for the treatment of Parkinson's Disease
DNA 20
1140 OBrien Drive Suite A	Menlo Park	CA	94025	743076460	Public Sector	9815	LRRK2 HD-Ad5
Duke University
CARL Bldg Research Dr Room 487	Durham	NC	27710	560532129	501(c)(3)	125000	Targeting beta-arrestin signaling in the treatment of Parkinson's disease
East Tennessee State University
PO Box 707577	Johnson City	TN	37614	626021046	501(c)(3)	74987	A genetic strategy to restore impaired noradrenergic function by increasing expression of noradrenergic phenotypes in the locus coeruleus in Parkinson's disease model mice
Eli Lilly & Co Ltd
XXXXX XXXXXX	Indianapolis	IN	46285	350470950	Public Sector	247840	Identification of alpha-synuclein molecular forms correlating with clinicopathology of Parkinson's disease
Emerald BioStructures
3 Preston Court	Bedford	MA	01730	911821586	Public Sector	1343780	LRRK2 Biological Structure and Function
Emerald Print Management
1100 University Avenue Suite 142-B	Rochester	NY	14607	010803249	Public Sector	5894	PPMI 2012: April Label Order #2
Emerald Print Management
1100 University Avenue Suite 142-B	Rochester	NY	14607	010803249	Public Sector	6785	PPMI 2012: April 2012 Label Order #1
Emory University
1841 Clifton Road Third Floor	Atlanta	GA	30329	580566256	501(c)(3)	9688	PPMI 2012: rsMRI Ancillary Study
Emory University
1841 Clifton Road Third Floor	Atlanta	GA	30329	580566256	501(c)(3)	14531	PPMI 2012: Cognitive Categorization Ancillary Study
Emory University
1510 Clifton Rd Rm 3001	Atlanta	GA	30322	580566256	501(c)(3)	25000	Role of PARK18 in Parkinson's Disease
Emory University
1841 Clifton Road Third Floor	Atlanta	GA	30329	580566256	501(c)(3)	155000	PPMI Clinical Trial Site: Year Two
Emory University
954 Gatewood Road NE	Atlanta	GA	30322	580566256	501(c)(3)	250000	Antiparkinsonian effects of T-type calcium channel inhibitors
Envoy Therapeutics
555 Heritage Drive	Jupiter	FL	33458	262535708	Public Sector	1267034	A New Mechanism for Highly Selective Modulation of the Indirect Pathway
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	6727	Alpha-Synuclein S129 -- IgG cloning and batch production
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	6727	LRRK1 IgG Cloning & Batch Production
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	8361	Epitomics Antibodies for LRRK2 ELISA Development by Covance
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	13454	pLRRK2 -- IgG Cloning Supplement for S955 and S97 3 Antibodies
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	31802	LRRK2 PS1292 Antiobody Production
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	57276	Phospho-Specific Antibody Generation
Eureka Genomics
410 Pierce Street Suite 307	Houston	TX	77002	261320502	Public Sector	19975	Whole genome sequencing of LRRK2 mouse transgenic lines
Feinstein Institute for Medical Research
350 Community Drive Research Build	Manhasset	NY	11030	112673595	501(c)(3)	578941	Network Biomarkers for the Assessment of Parkinson's Disease: A Multi-modal Optimization Study
FPRT Bio Inc
PO Box 1335	Winthrop	WA	98862	454804420	Public Sector	361700	Peripheral administration of XPro1595 in the rat 6-OHDA model of Parkinson's disease
Genentech
1 DNA Way	South San Francisco	CA	940804990	460500264	Public Sector	292780	Non-human Primate Safety Study of LRRK2 Inhibitors cognitive disorders in Parkinson's disease
Harvard University
243 Charles St	Boston	MA	02115	042103580	501(c)(3)	125000	Non-Invasive Striatal Delivery of Glial Derived Neurotrophic Factor(GDNF) via a Novel Heterotopic Mucosal Grafting Technique
Henry Ford Hospital
6777 West Maple Road	Detroit	MI	48322	381357020	501(c)(3)	147093	Small-molecule PD biomarkers: a metabolomic analysis
Indiana University
410 West Tenth Street HS 4000	Indianapolis	IN	462023002	356001673	501(c)(3)	7900	Aliquoting and shipping of DATATOP samples
Indiana University
410 West Tenth Street HS 4000	Indianapolis	IN	462023002	356001673	501(c)(3)	576248	Consortium to Identify LRRK2 Modifiers of Age of Onset
Johns Hopkins University
600 N Wolfe Street Meyer 6-119B	Baltimore	MD	21287	520595110	501(c)(3)	9688	PPMI 2012: rsMRI Ancillary Study
Johns Hopkins University
600 N Wolfe Street Meyer 6-119B	Baltimore	MD	21287	520595110	501(c)(3)	10781	PPMI 2012: Cognitive Categorization Ancillary Study
Johns Hopkins University
600 N Wolfe Street Meyer 6-119B	Baltimore	MD	21287	520595110	501(c)(3)	50000	AV-133: PPMI Ancillary Study
KineMed Inc
5980 Horton Street Suite 470	Emeryville	CA	94608	912104596	Public Sector	1190319	Cross-sectional examination of cerebrospinal fluid kinetic biomarkers of axonal transport for Parkinson disease diagnosis and progression
LZ Therapeutics Inc
490 Lapp Rd	Malvern	PA	19355	223930731	Public Sector	89480	Evaluation of the Effects of Human Cell Derived GM1 Ganglioside in the MPTP Lesioned Mouse Model of Parkinson's Disease
Massachusetts General Hospital
114 16th Street Room 2007	Boston	MA	02129	042697983	501(c)(3)	137896	Generation and characterization of iPS neurons from genetic Parkinson's Disease
Massachusetts General Hospital
Fruit Street WACC 715	Boston	MA	02114	042697983	501(c)(3)	212439	Neuroimaging Markers Predict Cognitive Decline in PD
Max Planck Florida Institute
5353 Parkside Drive MC19-RE	Jupiter	FL	334582906	262117502	501(c)(3)	20240	Design of HdAd Type 5 LRRK2 expression vectors
Max Planck Florida Institute
5353 Parkside Drive MC19-RE	Jupiter	FL	334582906	262117502	501(c)(3)	36947	Quality Control of HdAd Type 5 LRRK2 viral vectors
Mayo Clinic
13400 E Shea Blvd	Scottsdale	AZ	85259	593337028	501(c)(3)	15000	Adler compensation for role APDC
McLean Hospital
115 Mill St	Belmont	MA	02478	042697981	501(c)(3)	250000	Does peripheral immune challenge exacerbate LRRK2-induced neuronal pathology?
Medical University of South Carolina
326 Calhoun Street Suite 308	Charleston	SC	29425	576000722	501(c)(3)	459095	Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease
Metabolic Solutions Development Company
161 E Michigan Ave 4th Floor	Kalamazoo	MI	49007	900736237	Public Sector	210939	Potential of Novel Insulin Sensitizers to Treat Dyskinesia
Michigan State University
333 Bostwick Ave NE	East Lansing	MI	49503	386005984	501(c)(3)	75000	Nigrostriatal alpha-synuclein overexpression in young and aged rats LRRK
Michigan State University
333 Bostwick Ave NE	East Lansing	MI	49503	386005984	501(c)(3)	200000	Alpha-Synuclein Aggregation Leads to Loss of Functional Forms of the Protein and Toxicity.
Michigan State University
333 Bostwick Ave NE	East Lansing	MI	49546	386005984	501(c)(3)	270582	Amitriptyline as a dopamine neuroprotective therapy.
NINDS
6001 Executive Blvd Suite 2203	Bethesda	MD	20892	520858115	501(c)(3)	100000	iPSC Agreement
National Institute on Aging
35 Convent Drive Building 35 Room	Bethesda	MD	20892	522038294	501(c)(3)	122165	Non-kinase targets in LRRK2 biology
Neuroscience Associates
10915 Lake Ridge Drive	Knoxville	TN	379344919	621540123	Public Sector	68610	Pathological Characterization of Wildtype Rats as a controls for CJ LRRK2 Rats
Neuroscience Associates
10915 Lake Ridge Drive	Knoxville	TN	379344919	621540123	Public Sector	172633	Pathological characterization of aged KO rats
Neuroscience Associates
10915 Lake Ridge Drive	Knoxville	TN	379344919	621540123	Public Sector	245874	Pathological Characterization of aSyn mouse models
New York Institute of Technology
Northern Boulevard Riland Building	Old Westbury	NY	115688000	111788788	501(c)(3)	75000	The Effects of Tyrosine on Orthostatic Hypotension in Parkinson's Disease
Northwestern University
710 North Lake Shore Drive 1425 A	Chicago	IL	60611	362167817	501(c)(3)	9688	PPMI 2012: rsMRI Ancillary Study
Northwestern University
710 North Lake Shore Drive 1425 A	Chicago	IL	60611	362167817	501(c)(3)	16406	PPMI 2012: Cognitive Categorization Ancillary Study
Northwestern University
710 North Lake Shore Drive 1425 A	Chicago	IL	60611	362167817	501(c)(3)	28534	PPMI 2012: Steering Committee Support for Tanya Simuni
Northwestern University
710 North Lake Shore Drive 1425 A	Chicago	IL	60611	362167817	501(c)(3)	112500	PPMI 2012: Consulting Support for rsMRI Sub- study (2012-2015)
Northwestern University
710 North Lake Shore Drive 1425 A	Chicago	IL	60611	362167817	501(c)(3)	186250	PPMI Clinical Trial Site: Year Two
Octagon Research Solutions Inc
585 E Swedesford Road Suite 200	Wayne	PA	19087	233022539	Public Sector	38000	eCTD IND Submission for the AVE8112 MAD study
Oregon Health & Science University
3181 SW Sam Jackson Park Rd OP-32	Portland	OR	97239	931176109	501(c)(3)	15938	PPMI 2012: Cognitive Categorization Ancillary Study
Oregon Health & Science University
3181 SW Sam Jackson Park Road	Portland	OR	97239	931176109	501(c)(3)	30000	Investigation of possible pathological changes in aged LRRK2 knockout rats
Parexel
1560 Chevy Chase Drive Suite 140	Glendale	CA	91206	043517643	Public Sector	211800	Parexel Regulatory Services-Sanofi Trial
Parexel
1560 Chevy Chase Drive Suite 140	Glendale	CA	91206	043517643	Public Sector	1116184	Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients with Parkinson's Disease
Parkinson's Action Network
1025 Vermont Ave NW Suite 1120	Washington	DC	20005	943172675	501(c)(3)	250000	PAN Funding 2012
Parkinson's Disease and Movement Disorder C
951 NW 13th Street Bldg 5-E	Boca Raton	FL	33486	223659456	501(c)(3)	14063	PPMI 2012: Cognitive Categorization Ancillary Study
Pfizer Global Research and Development
Eastern Point Road	Groton	CT	06340	141396954	Public Sector	216934	LRRK2 PET Tracer Development
Promentis Pharmaceuticals
826 N Plankinton Ave Suite 4000	Milwaukee	WI	80021	753234358	Public Sector	299384	Targeting System-xc for the Treatment of Parkinson's Disease
Proteos
4717 Campus Drive	Kalamazoo	MI	49008	260069252	Public Sector	31003	Asyn Filament Antibody
Proteos
4717 Campus Drive	Kalamazoo	MI	49008	260069252	Public Sector	69311	Post-Translationally Modified Alpha-Synuclein: Generation of Alpha-Synuclein Protein
PsychoGenics
765 Old Saw Mill River Road Suite	Tarrytown	NY	10591	134034631	Public Sector	206000	Supplement to Phenotyping assessment of a DJ1 and Pink1 KO rats for PD
Purdue University
550 Stadium Mall Dr	West Lafayette	IN	47907	356002041	501(c)(3)	250000	Parkinson's and inflammatory bowel diseases: interaction in LRRK2 transgenic rats
QR Pharma
1055 Westlakes Drive Suite 300	Berwyn	PA	19312	262540421	Public Sector	468640	Development of Posiphen to treat Parkinson's Disease
Rush University
1735 West Harrison Street Suite 30	Chicago	IL	60612	362174823	501(c)(3)	31250	Rush University Tissue Resource
Rush University
1725 W Harrison St Suite 755	Chicago	IL	60612	362174823	501(c)(3)	111875	BioFIND Clinical Trial Site: Rush University
Rush University
1735 West Harrison Street Suite 30	Chicago	IL	60612	362174823	501(c)(3)	491803	The transfer of alpha-synuclein: Mechanistic and therapeutic studies
Rush University
1725 W Harrison Suite 755	Chicago	IL	60612	362174823	501(c)(3)	1007721	TOPIRAMATE AS AN ADJUNCT TO AMANTADINE IN THE TREATMENT OF DYSKINESIA IN PARKINSON'S Disease
Sanford-Burnham Institute for Medical Research
10901 N Torrey Pines Rd	La Jolla	CA	92037	510197108	501(c)(3)	124320	Protein S-Nitrosylation as a Potential Biomarker for Parkinson's Disease
Sensonics Inc
PO Box 112	Haddon Heights	NJ	08035	232225611	Public Sector	25710	PPMI 2012: 1st Batch Order of UPSITS for Prodromal PPMI (P-PPMI) - Dec 2012
Sigma-Aldrich
2033 Westport Center Drive	St Louis	MO	63146	841656258	Public Sector	6496	Sage LRRK2 KO Rat Pathology Study
Sigma-Aldrich
1140 OBrien Drive suite A	Menlo Park	CA	94025	841656258	Public Sector	204538	Sigma-Cell Lines
Southern Research Institute
2000 Ninth Ave South	Birmingham	AL	35205	630288868	501(c)(3)	59956	VILIP-1 as diagnostic and prognostic biomarker for Parkinson's Disease
Stanford University
300 Pasteur Drive Room H3160	Stanford	CA	94305	941156365	501(c)(3)	237525	Small molecule ligand for TrkB/TrkC as a novel therapeutic for Parkinson's Disease
Stanford University
1201 Welch Rd MSLS Building P304	Stanford	CA	943055487	941156365	501(c)(3)	249896	The Four Horsemen of G2019S
State University of New York at Binghamton
4400 Vestal Parkway East Science 4	Binghamton	NY	13902	141368361	501(c)(3)	74944	Potential of concomitant targeting of 5-HT1A and 5-HT2A receptors against L-DOPA induced dyskinesia in the hemi-parkinsonian rat model
SUNY Downstate Medical Center
450 Clarkson Ave	Brooklyn	NY	11203	141368361	501(c)(3)	311521	Intrinsic Remodeling of the Fovea in Parkinson's Disease
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	Public Sector	55162	Breeding and aging of aSyn mouse models at Taconic
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	Public Sector	55399	Breeding and Aging of SD Wildtype Littermate Rats as controls for CJ Li LRRK2 Rats
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	Public Sector	80363	Housing of CJ Li-generated BAC LRRK2 rats at Taconic
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	Public Sector	100000	Taconic additional housing and breeding supplement
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	Public Sector	174051	Housing of CJ Li-generated BAC alpha-synuclein rats at Taconic
Texas A&M University
Department of Pathobiology 218 VMA	College Station	TX	77843	742245072	501(c)(3)	150000	The role of alpha-synuclein in the pathogenesis of Parkinson's disease in a rat model- SUPPLEMENT
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06511	061582206	501(c)(3)	6000	PPMI Data Entry for Q1 2012
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	NEW HAVEN	CT	06511	061582206	501(c)(3)	7500	PPMI Data Entry for Q2 2012
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06511	061582206	501(c)(3)	7500	PPMI Data Entry for Q3 2012
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06511	061582206	501(c)(3)	22969	PPMI 2012: Cognitive Categorization Ancillary Study
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	23750	PPMI 2012: Leadership Core Support for AV133 Sub Study
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06511	061582206	501(c)(3)	50000	AV-133: PPMI Ancillary Study
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	60000	PPMI 2012: Leadership Core Support for P-PPMI
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	114000	PPMI 2012: Imaging Core Support for rsMRI Sub study
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	166667	PPMI 2012: 2013 Imaging Core Support for P-PPMI (LRRK2)
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	176250	PPMI 2012: Imaging Core Support for AV133 Sub study
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	333333	PPMI 2012: 2013 Imaging Core Support for P-PPMI
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06511	061582206	501(c)(3)	350000	PPMI 2012: Olfactory Core Support
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	352678	PPMI 2012: Leadership Core Year 3 Funding Support
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	500000	PPMI 2012: Site Support for Prodromal PPMI (P-PPMI) through Leadership Core - Dec 2012
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	501(c)(3)	621284	PPMI 2012: Imaging Core - Year 3 Funding Support
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	04609	010211513	501(c)(3)	7000	GBA knockin mouse rederivation and housing
The Jackson Laboratory
600 Main Street	Bar Harbor	ME	04609	010211513	501(c)(3)	96591	Breeding and aging of aSyn mouse models at JAX
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	10781	PPMI 2012: Cognitive Categorization Ancillary Study
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	36632	PPMI 2012: 2012 Steering Committee Support for Carolline Tanner
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94089	943061594	501(c)(3)	51984	Assessing Heart Rate Variability (HRV) in the Parkinson's Associated Risk Study (PARS) Cohort - Part 2
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94089	943061594	501(c)(3)	100000	2012 Pritzker Prize - winner
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	138996	The effects of memantine on L-DOPA induced dyskinesias in MPTP-treated squirrel monkeys
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	229406	PPMI Clinical Trial Site: Year Two
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	249764	Establishing LRRK2 Signaling Pathways
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	278444	Combined therapy with amantadine and fenobam for L-DOPA induced dyskinesias in MPTP- treated squirrel monkeys
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	411020	Bay Area Solvent Study - Symptoms (BASS-S)
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	475375	Parkinson's Institute LRRK2 cohort: clinical phenotype, pre/non-motor and environmental risk assessment
The Salk Institute for Biological Studies
10010 N Torrey Pines Road	La Jolla	CA	920371099	952160097	501(c)(3)	75000	A Pair of Neurotrophic Factor Inducing Drug Candidates
Thomas Jefferson University
1020 Locust Street 521 JAH	Philadelphia	PA	19107	232829095	501(c)(3)	74967	Enzymatic Degradation of Brain Complex Gangliosides to Increase Endogenous GM1 Levels: Potential Neuroprotective/ Neurorestorative Therapy For Parkinson's Disease
Thomas Jefferson University
900 Walnut Street-JHN Suite 462	Philadelphia	PA	19107	232829095	501(c)(3)	114618	Characterization of the hTH-GFP rat
Thomas Jefferson University
900 Walnut Street-JHN Suite 462	Philadelphia	PA	19107	232829095	501(c)(3)	139380	Gremlin-1 a putative VTA-derived Neuroprotective Factor in Parkinson's disease
Thomson Reuters
169 Saxony Road Suite 104	Encinitas	CA	92024	231569117	Public Sector	19000	Grant Outcomes Analysis
University of Alabama at Birmingham
1719 6th Ave South CIRC 516	Birmingham	AL	352940021	636005396	501(c)(3)	15469	PPMI 2012: Cognitive Categorization Ancillary Study
University of Alabama at Birmingham
1530 3rd Avenue South	Birmingham	AL	352941150	636005396	501(c)(3)	125047	Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease
University of Alabama at Birmingham
1719 6th Ave S CIRC 516	Birmingham	AL	35294	636005396	501(c)(3)	200000	Role of LRRK2 in alpha-synuclein-induced neurodegeneration
University of Arizona
1501 N Campbell Ave PO Box 2450	Tucson	AZ	857245023	742652689	501(c)(3)	75000	Opioid glycopeptides for the treatment of levodopa-induced dyskinesias
University of California Berkeley
127 Morgan Hall	Berkeley	CA	94720	946002123	501(c)(3)	250000	Monoacylglycerol Lipase as a Novel Target for Combatting Parkinson's Disease
University of California Los Angeles
635 Charles E Young Drive South	Los Angeles	CA	900957334	956006143	501(c)(3)	14583	PPMI 2012: Bioinformatics Core Support for Prodromal PPMI (P-PPMI) in 2013 - LRRK2 Contribution
University of California Los Angeles
635 Charles E Young Drive South S	Los Angeles	CA	900957334	956006143	501(c)(3)	29167	PPMI 2012: Support for Bioinformatics Core for Prodromal PPMI (P-PPMI) in 2013
University of California Los Angeles
635 Charles E Young Drive South S	Los Angeles	CA	900957334	956006143	501(c)(3)	33750	PPMI 2012: Bioinformatics Core Support for rsMRI Sub study
University of California Los Angeles
635 Charles E Young Drive South S	Los Angeles	CA	900957334	956006143	501(c)(3)	49375	PPMI2012: Bioinformatics Core Support for AV 133 Sub study
University of California Los Angeles
635 Charles E Young Drive South S	Los Angeles	CA	900957334	956006143	501(c)(3)	53750	PPMI 2012: Bioinformatics Core Support for Cognitive Categorization Ancillary Study
University of California Los Angeles
635 Charles E Young Drive South S	Los Angeles	CA	900957334	956006143	501(c)(3)	315928	PPMI 2012: Bioinformatics Core Year 3 Funding Support
University of California San Diego
9500 Gilman Drive 0662	San Diego	CA	920930662	952544535	501(c)(3)	7031	PPMI 2012: Cognitive Categorization Ancillary Study
University of California San Francisco
4150 Clement St 114M	San Francisco	CA	94121	946036493	501(c)(3)	97961	PPMI 2012: Year 3 Funding Support for DTI Core
University of California San Francisco
1650 Owens Street	San Francisco	CA	94158	946036493	501(c)(3)	200000	Normal role of synuclein in mitochondrial bioenergetics at the synapse
University of California San Francisco
1855 Folsom St Box 555 MCB Room	San Francisco	CA	94103	946036493	501(c)(3)	2036664	A Phase 1 Bridging Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MRI-Guided Real-Time Convective Infusion in the Putamen of Subjects with Parkinson's Disease
University of Chicago
5841 S Maryland Avenue MC 2030	Chicago	IL	60637	362177139	501(c)(3)	48202	A Small Molecule Approach to Correct Striatal Cholinergic Interneuron Dysfunction
University of Chicago
924 East 57th Street Knapp Center	Chicago	IL	60637	362177139	501(c)(3)	75000	Reversing pre-existing pathologies of DA neurons in a novel inducible human alpha- synuclein transgenic mouse model.
University of Chicago
5841 S Maryland Avenue MC 2030	Chicago	IL	60637	362177139	501(c)(3)	95829	BioFIND- Oversite PI award
University of Chicago
5841 S Maryland Ave MC2030 Room	Chicago	IL	60637	362177139	501(c)(3)	111875	BioFIND Clinical Trial Site: University of Chicago
University of Cincinnati
260 Stetson St Suite 2300	Cincinnati	OH	45267	316000989	501(c)(3)	14063	PPMI 2012: Cognitive Categorization Ancillary Study
University of Cincinnati
3225 Eden Ave 136 HPB	Cincinnati	OH	45267	316000989	501(c)(3)	74999	THE MIFUNCTIONAL CEMBRANOIDS FOR THERAPY OF PARKINSON'S DISEASE
University of Cincinnati
260 Stetson St Suite 2300	Cincinnati	OH	45267	316000989	501(c)(3)	326969	PPMI Clinical Trial Site
University of Colorado Denver
12850 E Montview Blvd Mail Stop	Aurora	CO	800452605	846000555	501(c)(3)	415151	Optimizing Glyoxylate Metalloporphryins for Clinical Development in Parkinson's disease: Evaluation in the Rat 6OHDA Model
University of Florida
100 S Newell Dr Room L1-100A	Gainesville	FL	32610	596002052	501(c)(3)	79482	In Vivo Characterization of Helper-Dependent Adenoviral Vectors Expressing Human LRRK2
University of Florida
100 S Newell Dr Room L1-100A	Gainesville	FL	32610	596002052	501(c)(3)	273186	Development of appropriate control transgenes for long term viral vector mediated gene transfer and optical imaging in the Nigra
University of Iowa
2450 University Capitol Center	Iowa City	IA	52242	426004813	501(c)(3)	9167	PPMI 2012: 2013 Statistics Core Support for P-PPMI (LRRK2)
University of Iowa
2450 University Capitol Center	Iowa City	IA	52242	426004813	501(c)(3)	18333	PPMI 2012: 2013 Statistics Core Support for P-PPMI
University of Iowa
2450 University Capitol Center	Iowa City	IA	52242	426004813	501(c)(3)	215426	PPMI 2012: Statistics Core Year 3 Funding Report
University of Michigan
1500 East Medical Center Drive	Ann Arbor	MI	481090028	386006309	501(c)(3)	1000000	The Role of A-beta in the Progression of Cognitive Impairment in PD: A Prospective Cohort Study
University of Minnesota
516 Delaware St SE 12-146 P W B	Minneapolis	MN	55455	416007513	501(c)(3)	116775	BioFIND Clinical Trial Site: University of Minnesota
University of North Carolina at Chapel Hill
101 Manning Drive	Chapel Hill	NC	27599	566001393	501(c)(3)	6579	HD-AD5 UNC SMALL BATCH/ DISTRIBUTION
University of Pennsylvania
330 South 9th Street	Philadelphia	PA	19104	231352685	501(c)(3)	13594	PPMI 2012: Cognitive Categorization Ancillary Study
University of Pennsylvania
330 South 9th Street	Philadelphia	PA	19107	231352685	501(c)(3)	28813	PPMI 2012: 2012 Steering Committee Support for Andrew Siderowf
University of Pennsylvania
125 S 31st Street	Philadelphia	PA	19104	231352685	501(c)(3)	30122	PPMI: Support for Ethics Component of Prodromal Study
University of Pennsylvania
330 South 9th Street	Philadelphia	PA	19104	231352685	501(c)(3)	50000	AV-133: PPMI Ancillary Study
University of Pennsylvania
3600 Spruce St Maloney Bldg 3rd	Philadelphia	PA	19104	231352685	501(c)(3)	124984	Evaluation of the Microtubule-Stabilizing Agent, Epothilone D, in Mouse Models of Parkinson's Disease
University of Pennsylvania
330 South 9th Street	Philadelphia	PA	19104	231352685	501(c)(3)	147500	PPMI Clinical Trial Site: Year Two
University of Pennsylvania
3400 Spruce Street 7103 Founders	Philadelphia	PA	19104	231352685	501(c)(3)	300134	PPMI 2012: Year 3 Funding Support for Bioanalytics Core
University of Rochester
919 Westfall Road Building C Suit	Rochester	MI	14618	263800000	501(c)(3)	11719	PPMI 2012: Cognitive Categorization Ancillary Study
University of Rochester
265 Crittenden Blvd	Rochester	NY	14620	263800000	501(c)(3)	13500	Datatop Samples Statistical Support from CHET, University of Rochester- Supplement
University of Rochester
265 Crittenden Blvd	Rochester	NY	14620	263800000	501(c)(3)	15938	Datatop Samples Statistical Support from CHET, University of Rochester
University of Rochester
919 Westfall Road Building C Suit	Rochester	NY	14618	263800000	501(c)(3)	224500	PPMI Clinical Trial Site: Year 2
University of Rochester
265 Crittenden Blvd	Rochester	NY	14620	263800000	501(c)(3)	335000	CTCC-PI for Discovery Cohort
University of Rochester
1351 Mt Hope Avenue Suite 216	Rochester	NY	14620	263800000	501(c)(3)	852238	PPMI 2012: Year 3 Funding Support for the PPMI Clinical Core
University of South Florida
4001 East Fletcher Avenue 6th Floo	Tampa	FL	33613	593102112	501(c)(3)	16875	PPMI 2012: Cognitive Categorization Ancillary Study
University of South Florida
4001 East Fletcher Avenue 6th Floo	Tampa	FL	33613	593102112	501(c)(3)	173750	PPMI Clinical Trial Site: Year Two
University of Texas Health Science Center San An
7703 Floyd Curl Drive	San Antonio	TX	78229	741586031	501(c)(3)	125000	Novel cell-based strategy for GDNF delivery in Parkinson's disease
University of Washington
1660 S Columbian Way VA-PSHCS 11	Seattle	WA	98108	916001537	501(c)(3)	15469	PPMI 2012: Cognitive Categorization Ancillary Study
University of Washington
300 9th Ave RT Room 321	Seattle	WA	98124	916001537	501(c)(3)	74892	Phosphorylated alpha-synuclein species as biomarkers for diagnosis and progression in Parkinson's disease
University of Washington
1660 S Columbian Way VA-PSHCS 11	Seattle	WA	98108	916001537	501(c)(3)	170000	PPMI Clinical Trial Site: Year Two
UT Southwestern Medical Center at Dallas
5323 Harry Hines Blvd Mail Code 88	Dallas	TX	753908813	756002868	501(c)(3)	43915	Analysis of archived tissue from Parkin, DJ-1, PINK1 and LRRK2 KO rats
UT Southwestern Medical Center at Dallas
5323 Harry Hines Blvd Mail Code 88	Dallas	TX	753908813	756002868	501(c)(3)	275000	Mechanisms of cellular regulation and post- translational modification of LRRK2
Van Andel Research Institute
333 Bostwick Avenue NE	Grand Rapids	MI	49503	522000823	501(c)(3)	99779	Circulating microRNAs: a new paradigm for Parkinson's disease biomarker discovery
Vanderbilt University
PHV Suite 313 1601 23rd Ave Sout	Nashville	TN	37212	620476822	501(c)(3)	98894	Preferential loss of serotonin axon subtypes in depression in Parkinson's Disease
Virginia College of Osteopathic Medicine
1861 Pratt Drive Corp Res Ctr -	Blacksburg	VA	24060	542052107	501(c)(3)	189519	Cerium Oxide Nanoparticles in the Treatment of Parkinson's Disease - Toxicity & Biodistribution Studies
Virginia Commonwealth University
PO Box 980539	Richmond	VA	55905	546001758	501(c)(3)	107492	A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals with Parkinson's Disease
Washington State University Pullman
Dept VCAPP	Pullman	WA	991646520	916001108	501(c)(3)	74999	Development of Small Molecule Hepatocyte Growth Factor Mimetics for the Treatment of Parkinson's Disease
Washington University in St Louis
510 S Kingshighway Blvd	St Louis	MO	63110	430653611	501(c)(3)	200000	Alpha Synuclein Autoradiography Core
Weill Medical College of Cornell University
428 East 72nd Street Suite 400	New York	NY	10021	131623978	501(c)(3)	111875	BioFIND Clinical Trial Site: Cornell University
WIL Research Laboratories
1407 George Road	Ashland	OH	448058946	260564612	Public Sector	25500	Collection and storage of rodent brain and peripheral tissues- Supplement
WIL Research Laboratories
1407 George Road	Ashland	OH	448058946	260564612	Public Sector	63000	Phenotypic Characterization of Wildtype Rats as a controls for CJ LRRK2 Rats
WIL Research Laboratories
1407 George Road	Ashland	OH	448058946	260564612	Public Sector	142500	SAGE LRRK2 KO RAT PATHOLOGY STUDY
WIL Research Laboratories
1407 George Road	Ashland	OH	448058946	260564612	Public Sector	315000	Behavioral Characterization of aSyn mouse models
World Parkinson Coalition Inc
1359 Broadway Suite 1509	New York	NY	10018	571206493	501(c)(3)	51555	3rd World Parkinson Congress (WPC 2013)
XenoPort
3410 Central Expressway	Santa Clara	CA	95051	943330837	Public Sector	347075	Novel Fumarate Esters as Neuroprotective Agents in Parkinson's Disease

Field	Value	IRS element (for citing)
Total Nbr Of501 C3 And Govt Grants	167	TotalNbrOf501C3AndGovtGrants
Total Nbr Of Other Organizations	55	TotalNbrOfOtherOrganizations

Form990 Schedule I Part IV Form990ScheduleIPartIV

Field	Value	IRS element (for citing)
Identifier	SCHEDULE I, PART I, LINE 2	Identifier
Return Reference	PROCEDURES FOR MONITORING GRANT FUNDS IN THE UNITED STATES:	ReturnReference
Explanation	THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.	Explanation

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Form990 Of Other Organizations	X	Form990OfOtherOrganizations
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	false	SeverancePayment
Supplemental Nonqual Retire Plan	false	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	false	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	false	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	false	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	false	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	false	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	false	AnyNonFixedPayments
Initial Contract Exception	false	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (10 entries)

TitleTitle	Base Compensation Filing OrgBaseCompensationFilingOrg	Comp Based On Related OrgsCompBasedOnRelatedOrgs	Bonus Filing OrgBonusFilingOrg	Bonus Related OrgsBonusRelatedOrgs	Other Compensation Filing OrgOtherCompensationFilingOrg	Other Compensation Related OrgsOtherCompensationRelatedOrgs	Deferred Comp Filing OrgDeferredCompFilingOrg	Deferred Comp Related OrgsDeferredCompRelatedOrgs	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs	Total Compensation Filing OrgTotalCompensationFilingOrg	Total Compensation Related OrgsTotalCompensationRelatedOrgs	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg	Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
Todd Sherer
CEO	280616	0	165000	0	0	0	7500	0	18590	0	471706	0	0	0
Joanne Martz
Chief Fin and Admin Officer	215473	0	80000	0	0	0	7500	0	12548	0	315521	0	0	0
Deborah W Brooks
Co-Founder & Exec. Vice Chair	300660	0	210000	0	0	0	7500	0	18590	0	536750	0	0	0
Sohini Chowdhury
Sr. VP, Research Partnerships	180396	0	30000	0	0	0	6312	0	6140	0	222848	0	0	0
Sheila Kelly
VP, Development	165363	0	19500	0	0	0	5546	0	6139	0	196548	0	0	0
Holly Teichholtz
VP, Marketing & Communications	130286	0	15000	0	0	0	4359	0	12548	0	162193	0	0	0
Brian K Fiske
VP, Research Programs	169200	0	17500	0	0	0	5387	0	12548	0	204635	0	0	0
Mark A Frasier
VP, Research Programs	160352	0	17500	0	0	0	5335	0	0	0	183187	0	0	0
Alison Urkowitz
VP, Research Operations	132290	0	13000	0	0	0	4359	0	6140	0	155789	0	0	0
Laxmi Wordham
Chief Digital Officer	200440	0	30000	0	0	0	6913	0	18590	0	255943	0	0	0

Form990 Schedule J Part III Form990ScheduleJPartIII

Field	Value	IRS element (for citing)
Identifier	DETERMINATION OF COMPENSATION FOR OFFICERS	Identifier
Return Reference	SCHEDULE J, PART I, QUESTION 3	ReturnReference
Explanation	Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually.	Explanation

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArt
Art Historical Treasures		ArtHistoricalTreasures
Art Fractional Interest		ArtFractionalInterest
Books And Publications		BooksAndPublications
Clothing And Household Goods		ClothingAndHouseholdGoods
Cars And Other Vehicles		CarsAndOtherVehicles
Boats And Planes		BoatsAndPlanes
Intellectual Property		IntellectualProperty

Securities Publicly Traded SecuritiesPubliclyTraded

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Number Of Contributions	57	NumberOfContributions
Noncash Contribs Rptd F990	33493293	NoncashContribsRptdF990
Method Of Determining Revenues	FAIR VALUE	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Securities Closely Held Stock		SecuritiesCloselyHeldStock
Securities Prtnrshp Trust Intrsts		SecuritiesPrtnrshpTrustIntrsts
Securities Miscellaneous		SecuritiesMiscellaneous
Qualified Contrib Hist Struct		QualifiedContribHistStruct
Qualified Contrib Other		QualifiedContribOther
Real Estate Residential		RealEstateResidential
Real Estate Commercial		RealEstateCommercial
Real Estate Other		RealEstateOther
Collectibles		Collectibles
Food Inventory		FoodInventory
Drugs And Medical Supplies		DrugsAndMedicalSupplies
Taxidermy		Taxidermy
Historical Artifacts		HistoricalArtifacts
Scientific Specimens		ScientificSpecimens
Archaeological Artifacts		ArchaeologicalArtifacts
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts	true	ReviewProcessUnusualNCGifts
Third Parties Used	false	ThirdPartiesUsed

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (2 entries)

IdentifierIdentifier	ExplanationExplanation	Return ReferenceReturnReference
FORM 990, PAGE 1, LINE 1 AND PAGE 2, LINE 1	FINDING THE CURE FOR PARKINSONS TAKES AN ORGANIZATION WITH EXTRAORDINARY VISION. Actor Michael J. Fox established The Michael J. Fox Foundation for Parkinson's Research (the "Foundation"), incorporated in Delaware in 2000, after publicly disclosing in 1998 that he had been diagnosed with Parkinson's disease seven years earlier, at age 29. In 2009, The Michael J. Fox Foundation for Parkinson's Research in Canada ("MJFF Canada") was established as an officially registered tax-exempt charity in Canada. As this entity meets the criteria for consolidation, its financial statements are consolidated with those of the Foundation. As MJFF Canada's assets and liabilities and its operations were not significant at December 31, 2012 and 2011, they are not shown separately in the accompanying consolidated financial statements. The Foundation is exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code, and from state and local taxes under comparable laws. MJFF Canada is exempt from similar taxes under Canadian law. Today, The Michael J. Fox Foundation is the world's largest private funder of Parkinson's research. It is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $344 million in research as of December 31, 2012, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. In addition to funding a broad portfolio of investigator-initiated and priority-driven research programs, the Foundation is working to transform the medical research enterprise and shape a system that fosters, rather than inhibits, the development of cures. MJFF partners with the Parkinson's research community, speeding financial and intellectual resources to the scientists who can help realize ideas with the greatest promise to impact patients' lives. The Foundation has ignited collaboration among academic and industry players by requiring researchers to share information in real time. To enable scientists to move toward breakthroughs faster, MJFF has stepped up to meet their need for research tools. To date, the Foundation has funded work on over 100 therapeutic targets, and is supporting 60 clinical trials. Since its founding, MJFF has proven not only that a new kind of stakeholder can accelerate drug development - but that it is what was missing all along. While much has changed in the past decade, one thing remains constant: the Foundation's commitment to Parkinson's patients. Everything MJFF does is with patients in mind, at all stages of PD, which informs investments in disease-modifying therapies, better symptomatic treatments and new approaches to the symptoms entirely unaddressed by today's generation of drugs.
Form 990, Page 6	Line 2: BOARD MEMBER RELATIONSHIPS TWO BOARD MEMBERS ARE MARRIED TO ONE ANOTHER. TWO BOARD MEMBERS ARE IN-LAWS. Line 4: BY-LAW CHANGES DURING 2012, THE FOUNDATION REVISED ITS BY-LAWS. SIGNIFICANT CHANGES INCLUDE AN INCREASE IN THE MAXIMUM NUMBER OF DIRECTORS FROM 30 TO 50. Line 11A: Process for Review of Form 990: The Finance Committee of the Board of Directors, in association with external auditors, approves the annual IRS Form 990 which is then made available to the entire Board before it is filed. Line 12A: CONFLICT OF INTEREST POLICY Conflict of Interest Policy monitoring: Officers, directors and key employees complete a conflict of interest questionnaire annually. The information is reviewed by the Chief Financial and Administrative Officer, and conflicts are reviewed with the Board of Directors. Line 15: PROCESS FOR DETERMINING COMPENSATION Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually. Line 19: Governing documents are available upon request. - Conflict of interest policy is available upon request. - Financial statements are available at www.michaeljfox.org.	Governance, Management and Disclosure

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII

Name Of Disregarded Entity NameOfDisregardedEntity

Field	Value	IRS element (for citing)
Business Name Line1	MJFF CANADA	BusinessNameLine1

Address Foreign AddressForeign

Field	Value	IRS element (for citing)
Address Line1	365 Bay Street Suite 899	AddressLine1
City	Toronto	City
Province Or State	Ontario	ProvinceOrState
Country	CA	Country

Field	Value	IRS element (for citing)
Primary Activities	RESEARCH	PrimaryActivities
Legal Domicile Foreign Country	CA	LegalDomicileForeignCountry

Direct Controlling Entity Name DirectControllingEntityName

Field	Value	IRS element (for citing)
Business Name Line1	MJFF (US)	BusinessNameLine1

Field	Value	IRS element (for citing)
Controlled Org	false	ControlledOrg

Field	Value	IRS element (for citing)
Receipt Of Int Ann Rents Royalties	false	ReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other Org	false	GiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other Org	true	GiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other Org	false	LoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other Org	false	SaleOfAssetsToOtherOrg
Purchase Of Assets From Other Org	false	PurchaseOfAssetsFromOtherOrg
Exchange Of Assets	false	ExchangeOfAssets
Rental Of Facilities To Other Orgs	false	RentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other Orgs	false	RentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other Orgs	false	PerformOfServicesForOtherOrgs
Perform Of Services By Other Orgs	false	PerformOfServicesByOtherOrgs
Sharing Of Facilities	false	SharingOfFacilities
Sharing Of Paid Employees	false	SharingOfPaidEmployees
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrg
Reimbursement Paid By Other Org	false	ReimbursementPaidByOtherOrg
Other Transfer To Other Org	false	OtherTransferToOtherOrg
Other Transfer From Other Org	false	OtherTransferFromOtherOrg

Transactions Related Orgs Table TransactionsRelatedOrgsTable

Name Of Other Organization NameOfOtherOrganization

Field	Value	IRS element (for citing)
Business Name Line1	THE MICHAEL J FOX FOUNDATION (CANADA)	BusinessNameLine1

Field	Value	IRS element (for citing)
Transaction Type	C	TransactionType
Amount Involved	293559	AmountInvolved
Method Of Amt Determination	FMV	MethodOfAmtDetermination